Literature DB >> 7890431

Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.

M Dunne1, B K al-Ramadi, S W Barthold, R A Flavell, E Fikrig.   

Abstract

Borrelia burgdorferi is the causative agent of Lyme disease. In the mouse model, protection is correlated with the development of antibodies to a major outer surface protein, OspA. In this study, we expressed OspA in an attenuated strain of Salmonella typhimurium and tested the efficacy of the transformed strain in protecting against disease. We show that mice inoculated by gavage developed high titers of anti-OspA antibodies and were protected against an intradermal challenge with the spirochete.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890431      PMCID: PMC173199          DOI: 10.1128/iai.63.4.1611-1614.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Deer, ticks, and Lyme disease.

Authors:  C C Lastavica
Journal:  N Y State J Med       Date:  1992-01

2.  Incidence and prevalence of Lyme disease in a suburban Westchester County community.

Authors:  B Alpert; J Esin; S L Sivak; G P Wormser
Journal:  N Y State J Med       Date:  1992-01

3.  Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model.

Authors:  S N Chatfield; K Strahan; D Pickard; I G Charles; C E Hormaeche; G Dougan
Journal:  Microb Pathog       Date:  1992-02       Impact factor: 3.738

4.  Prevalence of antibody to Borrelia burgdorferi by indirect fluorescent antibody assay, ELISA, and western immunoblot in healthy adults in Wisconsin and Arizona.

Authors:  M M Huycke; D D D'Alessio; J J Marx
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

5.  Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice.

Authors:  E Fikrig; S R Telford; S W Barthold; F S Kantor; A Spielman; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

6.  Long-term protection of mice from Lyme disease by vaccination with OspA.

Authors:  E Fikrig; S W Barthold; F S Kantor; R A Flavell
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Comparison of antigen presentation of influenza A nucleoprotein expressed in attenuated AroA- Salmonella typhimurium with that of live virus.

Authors:  S J Brett; J Rhodes; F Y Liew; J P Tite
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.422

8.  Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA.

Authors:  E Fikrig; S W Barthold; F S Kantor; R A Flavell
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

9.  Development and duration of protection against salmonellosis in mice and sheep immunised with live aromatic-dependent Salmonella typhimurium.

Authors:  T K Mukkur; K H Walker
Journal:  Res Vet Sci       Date:  1992-03       Impact factor: 2.534

10.  Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

Authors:  C O Tacket; D M Hone; R Curtiss; S M Kelly; G Losonsky; L Guers; A M Harris; R Edelman; M M Levine
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

View more
  13 in total

1.  Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.

Authors:  Mark R Scheckelhoff; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2005-11-04       Impact factor: 3.641

2.  Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting.

Authors:  J R Creson; L C Lim; N J Glowacki; S M Callister; R F Schell
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

Review 3.  Development of bacteria as diagnostics and therapeutics by genetic engineering.

Authors:  Daejin Lim; Miryoung Song
Journal:  J Microbiol       Date:  2019-05-11       Impact factor: 3.422

Review 4.  Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.

Authors:  A Sadziene; A G Barbour
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

5.  Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.

Authors:  Luciana Meirelles Richer; Miguel Aroso; Tania Contente-Cuomo; Larisa Ivanova; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

6.  Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC.

Authors:  R D Gilmore; K J Kappel; M C Dolan; T R Burkot; B J Johnson
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

7.  Differential expression of the Bhmp39 major outer membrane proteins of Brachyspira hyodysenteriae.

Authors:  Timothy D Witchell; Scott A J Coutts; Dieter M Bulach; Ben Adler
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

8.  Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.

Authors:  Maarten J Voordouw; Haley Tupper; Özlem Önder; Godefroy Devevey; Christopher J Graves; Brian D Kemps; Dustin Brisson
Journal:  Vector Borne Zoonotic Dis       Date:  2013-02-21       Impact factor: 2.133

9.  Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1{beta}.

Authors:  Akinobu Kajikawa; Kazuya Masuda; Mitsunori Katoh; Shizunobu Igimi
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

10.  Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2009-05-14       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.